Company profile: Millendo Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical research and development, previously primarily focused on developing novel treatments for endocrine diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Millendo Therapeutics
Viking Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics in development targeting metabolic and endocrine disorders, including oral TRβ agonists (VK2809 for lipid/metabolic disorders incl. NASH; VK0214 for X-ALD), a dual GLP-1/GIP agonist (VK2735) for obesity, an oral FBPase inhibitor (VK0612) for type 2 diabetes, a DGAT-1 inhibitor (VK1430) for hypertriglyceridemia/NASH, and an oral non-steroidal SARM (VK5211) for recovery after non-elective hip fracture surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viking Therapeutics company profile →
Neurocrine Biosciences
HQ: United States
Website
- Description: Provider of therapies for neurological and endocrine-related diseases, including FDA-approved Ingrezza (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa and Oriahnn (commercialized by AbbVie) for endometriosis pain and heavy menstrual bleeding associated with uterine fibroids; and investigational Crinecerfont for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, NBI-1065890 (VMAT2 inhibitor), and NBI-1065845 (AMPA potentiator).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurocrine Biosciences company profile →
Baronova
HQ: United States
Website
- Description: Provider of clinical-stage medical devices under development to induce weight loss through non-surgical, non-pharmacologic approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baronova company profile →
Embark Biotech
HQ: Denmark
Website
- Description: Provider of biotech research identifying novel cell surface receptors that physiologically regulate fat tissue calorie-burning and glucose and lipid uptake; founded in 2017 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embark Biotech company profile →
Standard Bariatrics
HQ: United States
Website
- Description: Provider of surgical instruments for weight-loss surgeries, focused on sleeve gastrectomy. Offerings include Titan SGS, a surgical stapler with a 23 cm continuous staple line for consistent sleeve anatomy; Standard Precision Bougie Device for precise alignment and protection of the incisura angularis; Standard Trocar, a bladeless access device for introducing Titan SGS; and Standard Clamp to plan and hold the staple line, helping standardize technique and improve efficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Standard Bariatrics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Millendo Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Millendo Therapeutics
2.2 - Growth funds investing in similar companies to Millendo Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Millendo Therapeutics
4.2 - Public trading comparable groups for Millendo Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →